Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 64Cu-TLX592
64Cu-DOTA-TLX592 · 1 trial · 1 indication
Treatment emergent adverse events (TEAE) will be classified according to MedDRA (Medical Dictionary for Regulatory Activities), frequency, severity according to NCI CTCAE V5.0, seriousness, and relationship of study treatment will be assessed. Laboratory abnormalities will be assessed according to the NCI CTCAE v.5.0
Patient plasma samples at 0h, 1h, 4 ± 0.5h, 20 ± 4h and 48 ± 4h after the administration of 64Cu-TLX592 will be counted for radioactivity.
On Days 0, Day 1 and potentially at 36-120h after administration of the investigational product, the biodistribution and tumour imaging will be performed. An end of study visit will be conducted on Day 28 ± 2 days. 64Cu-TLX592 images will be centrally analysed for absorbed organ and whole body doses in a standardised fashion. In addition, tumour absorbed doses will be determined for scientific purposes (estimation of achievable tumour doses of therapeutic nuclides labelled to TLX592)
For dosimetry analysis, biodistribution whole body PET/CT imaging will be performed at 1h, 4 ± 0.5h, 20 ± 4h, with the option for a an additional two scans to be performed between the 36-120 hours.
| Arm | Type | Description |
|---|---|---|
| Dose level 1 of 64Cu-TLX592 | EXPERIMENTAL | Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu |
| Dose level 2 of 64Cu-TLX592 | EXPERIMENTAL | Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu combined with 8mg of unlabelled TLX592 (mass dose of 10mg). |
| Dose level 3 of 64Cu-TLX592 | EXPERIMENTAL | Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu combined with 18mg of unlabelled TLX592 (mass dose of 20mg). |
| Confirmation of optimal 64Cu-TLX592 dose | EXPERIMENTAL | Based on the result of Groups 1-3, the optimal dose and imaging timepoints will be selected to treat 3 patients with higher tumour burden (≥10 metastatic sites and/or visceral disease as detected on a 68Ga-PSMA-11 or 18F-DCFPyl PSMA PET/CT scan). Three patients will be intravenously administered with a single injection of 2mg of TLX592, labelled with 300 MBq (± 10%) 64Cu combined with 0, 8 or 18mg of unlabelled TLX592. |
| Name | Type | Description |
|---|---|---|
| 64Cu-DOTA-TLX592 | DRUG | TLX592, a humanised, engineered monoclonal antibody HuX592r conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592) |
Inclusion Criteria: * Written informed consent. * Biochemically recurrent metastatic adenocarcinoma of the prostate, or metastatic primary adenocarcinoma of the prostate. * Histologically or cytologically confirmed diagnosis of adenocarcinoma of prostate. * PSMA-expressing prostate adenocarcinoma a...
Top 20 of 55 competitors
64Cu-DOTA-TLX592 is an investigational small molecule imaging agent being developed by Telix Pharmaceuticals Limited for metastatic prostate cancer. It is designed to be used in PET imaging and is currently in Phase 1 clinical development. It has not been approved by the FDA.
64Cu-DOTA-TLX592 is being studied as a PET imaging agent for metastatic prostate cancer. The Phase 1 CUPID study evaluated its safety, pharmacokinetics, biodistribution, and dosimetry in patients with metastatic prostate cancer. It is investigational and has not been approved for clinical use.
64Cu-DOTA-TLX592 is being developed by Telix Pharmaceuticals Limited, an Australian radiopharmaceutical company that trades under the ticker TLX. Telix is the sponsor of the Phase 1 CUPID study evaluating the agent in metastatic prostate cancer.
64Cu-DOTA-TLX592 is in Phase 1 clinical development. The only trial of this agent, the CUPID study, was an early Phase 1 trial that has been completed. It is investigational and has not been approved by the FDA.
64Cu-DOTA-TLX592 has been studied in one clinical trial, NCT04726033, titled the 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study, also known as the CUPID Study. It was an early Phase 1 trial in metastatic prostate cancer that enrolled 14 male patients in Australia and is now completed.
Yes, 64Cu-DOTA-TLX592 is also referred to as 64Cu-TLX592. The CUPID Study, registered as NCT04726033, uses the shorter name 64Cu-TLX592 in its title. Both names refer to the same investigational PET imaging agent being developed by Telix Pharmaceuticals for metastatic prostate cancer.